Inhibition of novel molecular targets of prostaglandin formation for antitumor ac

抑制前列腺素形成的新分子靶点抗肿瘤活性

基本信息

批准号：
8658015
负责人：
Emmanuelle Joelle Meuillet
金额：
$ 29.47万
依托单位：
UNIVERSITY OF ARIZONA
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-07-01 至 2016-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8658015
关键词：
Affect Anabolism Animal Model Animals Anti-Bacterial Agents Anti-Inflammatory Agents Anti-inflammatory Applications Grants Arachidonic Acids Binding Biological Blood Pressure Brain Cancer Cell Growth Cardiotoxicity Catalytic Domain Cells Chemicals Colon Colon Carcinoma Colonic Neoplasms Computer Simulation Computing Methodologies Coxibs Dentistry Development Dinoprostone Docking Dose Drug Design Eicosanoids Engineering Enzymes Epoprostenol Exhibits Future Gene Deletion Genes Goals Homology Modeling Human In Vitro Inflammation Inflammation Process Inflammatory Interleukins Lead Libraries Lung Malignant Neoplasms Malignant neoplasm of lung Malignant neoplasm of pancreas Malignant neoplasm of prostate Membrane Metabolic Modeling Molecular Molecular Models Molecular Target Mus Oral Oral mucous membrane structure Pharmaceutical Preparations Phenols Phospholipase A2 Phospholipids Play Preparation Process Production Property Prostaglandin Endoperoxides Prostaglandin H2 Prostaglandin Inhibition Prostaglandins Protein Isoforms Proteins Regulation Role Spectrum Analysis Structure Study models Surface Plasmon Resonance Testing Triclosan Tumorigenicity Uncertainty Validation Work Xenograft procedure analog base cancer cell cancer initiation carcinogenesis cellular engineering colon cancer cell line cyclooxygenase 2 design drug development improved in vivo in vivo Model inhibitor/antagonist malignant breast neoplasm malignant stomach neoplasm molecular modeling mouse PGE synthase 1 mouse model novel novel strategies overexpression pharmacophore public health relevance simulation small molecule small molecule libraries therapeutic target tumor tumor growth tumor progression tumorigenic

项目摘要

DESCRIPTION (provided by applicant): Prostaglandin E2 (PGE2) plays an important role in cancer initiation and progression and inhibiting PGE2 synthesis offers an attractive way to inhibit cancer cell growth. Most studies to date have focused on inhibiting cyclooxygenase-2 (COX-2). While COX-2 inhibitors have shown anti-tumor activity animals and humans, the occurrence of cardiotoxicity associated with the use of high doses of COX-2 inhibitors has cast doubts as to their future use. Thus, alternative ways of selectively inhibiting PGE2 synthesis in cancer are needed. The final step in PGE2 synthesis is controlled by PGE2 synthases (PGESs) that isomerize PGH2 into PGE2. Two microsomal isoforms for mPGES (mPGES-1 and mPGES-2) and one cytosolic form (cPGES-3) have been identified. mPGES-1 is over-expressed in many cancers leading to increased levels of PGE2 while cells engineered to overexpress mPGES-1 show high levels of tumorigenicity. Deleting mPGES-1 in animals does not give rise to the cardiotoxicity typically associated with the use of COX-2 inhibitors. mPGES-1, thus, represents an attractive molecular target for inhibiting PGE2 biosynthesis and inhibiting tumor growth. We have used a structural homology model of mPGES-1 and docking simulations of chemical entities from chemical libraries to identify novel lead inhibitors of mPGES-1. The compounds exhibit activity in the high nanomolar range in cancer cells, with no off-target COX-2 activity and with promising anti-tumor activity in colon cancer cells xenografts. The objectives of our studies are 1) to conduct molecular mechanistic studies of the role of mPGES-1 in tumor and inflammatory stroma in the development of colon cancer; 2) to identify novel, potent, selective and efficacious inhibitors for mPGES-1 using rational structure-based design; 3) to synthesize focused libraries of analogs to improve biological activity, insure of selectivity and absence of cardiotoxicity; to impart drug like properties and to test select active analogs in vitro to provide a mechanistic rationale for their biological activity and 4) to test the anti-tumor properties of two of the lead compounds in two in vivo models of inflammatory colon cancer. The overall goal of our work is to develop novel agents for the improved treatment of colon cancer.

描述（由申请人提供）：前列腺素E2（PGE2）在癌症开始和进展中起重要作用，并且抑制PGE2合成提供了一种抑制癌细胞生长的有吸引力的方法。迄今为止，大多数研究都集中在抑制环氧合酶2（COX-2）上。尽管COX-2抑制剂已经显示出抗肿瘤活性动物和人类，但与使用高剂量的COX-2抑制剂有关的心脏毒性的发生对它们的未来使用产生了疑问。因此，需要选择性抑制癌症中PGE2合成的替代方法。 PGE2合成中的最后一步由将PGH2异构的PGE2合酶（PGESS）控制为PGE2。已鉴定出两个用于MPGE的微粒体同工型（MPGES-1和MPGES-2）和一种胞质形式（CPGES-3）。 MPGES-1在许多癌症中过表达，导致PGE2水平升高，而设计以过表达MPGES-1的细胞显示出高水平的肿瘤性。在动物中删除MPGES-1不会引起通常与使用COX-2抑制剂有关的心脏毒性。因此，MPGES-1代表了抑制PGE2生物合成和抑制肿瘤生长的有吸引力的分子靶标。我们已经使用了MPGES-1的结构同源模型和对化学文库的化学实体模拟模拟，以鉴定MPGES-1的新型铅抑制剂。这些化合物在癌细胞的高纳摩尔范围内表现出活性，没有脱靶Cox-2活性，并且在结肠癌细胞异种移植物中具有有希望的抗肿瘤活性。我们研究的目标是1）进行分子机械研究，以了解MPGES-1在肿瘤和炎症基质中的作用在结肠癌发展中的作用； 2）使用基于理性结构的设计来识别MPGES-1的新颖，有效，有效的抑制剂； 3）综合类似物的集中库，以改善生物学活性，确保选择性和缺乏心脏毒性；在体外赋予药物之类的药物，并在体外测试精选的活性类似物，以提供其生物学活性的机械基本原理，4）在两种体内炎症性结肠癌模型中，两种铅化合物的抗肿瘤性质。我们工作的总体目标是开发新的药物来改善结肠癌的治疗。